Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients
Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients undergoingcoronary artery bypass grafting (SCAN 1/17/96). Medco Research,of Research Triangle Park, NC, also developed cardiac stress agentAdenoscan, which is marketed by Fujisawa.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.